Valproic acid (VPA) is widely used in the treatment of epilepsy, particularly in the case of petit mal epilepsy. Free VPA is volatile and shows no characteristic absorption in the ultraviolet region (above 235 nm). Several derivatives of phenacyl, including trimethylsilyl (TMS), t-butyldimethylsilyl (t-BDMS) and 9-aminophenanthrene as a pretreatment for VPA have been used in the determination of VPA by GC or LC analysis. [1] [2] [3] [4] Liquid chromatography-atmospheric pressure chemical ionization mass spectrometry (LC-APCI-MS) using a soft ionization technique facilitates drug metabolism. It is well known that the addition of ammonium acetate to the mobile phase increases the intensity of quasimolecule ion production by APCI technique. 5 LC-APCI-MS has been successfully applied for the determination of several non-and low polar materials.
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The present authors improved the sensitivity of VPA determination by increasing the ion intensity of VPA quasimolecule by LC-APCI-MS. This was achieved by adding ammonium acetate to the injection solution. The method was applied to the analysis of human serum extract dosed with VPA.
In a previous work, we used LC-fluorometry 1 and GC-MS 6 for the determination of VPA. However, biological fluids contain complex matrices and each sample has to be pretreated using several cleaning techniques or has to be derivatized to identify the objective materials.
We examined the usefulness of sensitive quantification of serum VPA by LC-APCI-MS technique without chemical modification of VPA and with ammonium acetate added to the injection solution.
Experimental

Chemicals and stock solutions
VPA was obtained from Tokyo Kasei Kogyo, Ltd. (Tokyo, Japan). All other chemicals were commercially available guaranteed reagents, and were used without further purification. All solvents were of HPLC grade and other chemicals were of analytical reagent grade. Distilled or deionized water was used for all experiments.
Liquid chromatography-atmospheric pressure chemical ionization mass spectrometry (LC-APCI-MS)
LC-MS analysis was performed on a Hitachi M 1000 LC-APCI mass spectrometer connected to a Hitachi L-6200 HPLC pump (Hitachi, Tokyo, Japan).
To 20 µl of serum was added 0.48 µl of acetic acid-ammonium acetate buffer (pH 4.0) solution. The mixture was applied onto a solid phase column packed with 0.35 g of Extrelut packing materials, and allowed to stand for 20 min at room temperature. VPA was eluted from the Extrelut column with 12 ml of chloroform. To the eluate, 30 µl of 0.1 w/v% ammonium hydroxide in methanol was added, and the solution was mixed well. The mixtures were concentrated in vacuo at not more than 20˚C with a cooling trap. The concentrated residue was dissolved in 1.0 ml of 90% methanol: 0.1 mol/l acetic acid-ammonium acetate buffer (pH 4.0) (96:4, v/v) with vigorous stirring for 1 min, then filtered through a 0.4 µm membrane filter. Fifty microliters of the filtrate were directly injected onto LC-MS, which was interfaced with an APCI system. The chromatographic separation was performed using a Shim-pack CLC-ODS column (5-µm particle, 150 mm × 4.6 mm, i.d. Shimadzu, Japan). The mobile phase was 90% methanol.
The flow rate of the mobile phase was maintained at 1.0 ml/min. MS conditions were optimized in order to achieve maximal sensitivity. In the negative-ion mode, the optimal drift and focus voltage of the mass spectrometer were set at -40 V and -100 V, respectively. The temperatures of the vaporizer and desolvator were 200 and 399˚C, respectively. The multiplier voltage was set at 2400 V. Mass spectrometry was run in the selected-ion monitoring (SIM) mode on negative ion m/z 143[M-H] -for VPA.
Gas chromatography
Gas chromatography of VPA was performed according to the extractive methylation method reported by Nishioka et al. 7 To 20 µl of water or serum, 100 µl of VPA solution (100 µg/ml) and 0.38 ml of 50 mmol/l ammonium acetate buffer solution (pH 4.0) were added. The solution was mixed well, and then applied onto a solid phase column packed with 0.35 g of Extrelut. After a 20-min period of adsorption, VPA was eluted with 12 ml of chloroform. The resulting eluate was mixed well with 30 µl of 0.1 w/v% ammonium hydroxide in methanol and then concentrated in vacuo to oily materials. To the residue, 100 µl of 0.18 mol/l tetrabutylammonium chloride solution in 50 mmol/l phosphate buffer (pH 8.0), 100 µl of octanoic acid solution of 50 mmol/l phosphate buffer (pH 8.0) as an internal standard (100 µg/ml), and 0.5 ml of 1.0 mol/l methyl iodide solution in methylene chloride were added. The mixture was shaken vigorously for 30 min, then centrifuged at 7000g for 5 min. Ten microliters of the lower layer were injected into GC.
Results and Discussion
Effect of addition of ammonium acetate to the mobile phase
In LC-MS, the mobile phase composition should be volatile and easily expelled prior to inserting the sample into the mass spectrometer device. We examined the use of a methanol-water system as the mobile phase. Several optimal conditions were analyzed in order to improve the sensitivity of VPA determination by LC-APCI-MS.
The optimal conditions for the determination of VPA were determined to be as follows: 90% methanol as the mobile phase, 1.0 ml/min for the flow rate, 2400 V for the ionization voltage, and 220˚C for the vaporization temperature. All experiments were performed under these optimal conditions, and drift and focus voltage were set in order to obtain the highest quasimolecule ion peak in LC-APCI-MS. Consequently, the proton atom of VPA is easily removed by the negative charge.
Increases in the ion peak on mass spectrograms were examined by comparing positive and negative ionization modes. For the positive ionization mode (drift and focus voltages were set at 30 V and 110 V, respectively), peak monitoring was performed at m/z 145 using the protonated molecule ion of VPA as the SIM mode. The peak area on the mass chromatogram detected by negative mode monitoring was approximately 110 times larger than that by positive mode monitoring. Moreover, negative mode monitoring showed only a protonated ion peak (M-H) -without fragmentation. An increase in the ion peak occasionally occurred upon addition of ammonium acetate to the mobile phase according to negative ion monitoring in LC-APCI-MS, especially for organic acids. 5 The addition of ammonium acetate to the injection solution contributes to the increase in the intensity of quasimolecule VPA ions, in comparison with no addition of ammonium acetate (Fig. 1) .
In the proposed method using 90% methanol as the mobile phase, sensitivity was compared between injection solutions containing or not containing ammonium acetate. The molecule ion peak on the mass spectrogram for VPA solution dissolved in 90% methanol-0.1 mol/l ammonium acetate buffer (pH 4.0, 96:4, v/v) was found to be about ten times greater than that of VPA solution dissolved in only 90% methanol. The addition of ammonium acetate to the injection solution induced a remarkable increase in the base peak of VPA on the mass spectrogram.
Extraction of VPA from serum
VPA extracts extracted from serum using conventional organic solvents often form an emulsion. Moreover, for complete removal of proteins, it is not sufficient to simply add organic solvent to the serum. Therefore, the authors adopted the solid phase extraction method to achieve complete deproteinization of serum, which in turn leads to decontamination of the ion source and the prevention of mass detector deterioration.
VPA extraction from serum using Extrelut column reported by Nakajima et al. 1 has been improved, thereby resulting in a revised method applicable to the LC-MS measurements.
In the extraction procedure of VPA from serum, 0.1 mol/l acetic acid-ammonium acetate buffer solution was added to the serum. The optimal pH value of the ammonium acetate buffer was examined using solutions of pH 2.8, 3.0, 3.5 and 4.0. The highest peak area was observed at pH 4.0. Ammonium acetate buffer (pH 4.0) was utilized to adjust the pH value of the serum sample solution. In order to prevent loss due to evaporation of VPA at the step for concentration of the eluate, 0.1 w/v% ammonium hydroxide in methanol was added to the eluate before the concentration procedure in vacuo.
On the mass spectrum of VPA-spiked serum, a distinct quasimolecule ion [M-H] -peak of VPA was observed at m/z 143 ( Fig. 2A) .
In contrast, in the control serum, no quasimolecule ion peak was detected at m/z 143. By adopting the above experimental conditions, no interfering peak from the control serum against m/z 143 was observed.
Calibration curve of VPA
The calibration curves were plotted by means of least-square regression of the peak area of analytes vs. the nominal concentrations of the analyte. VPA concentrations were examined by the proposed method using the absolute calibration method. The calibration curve was created using the Extrelut extraction procedure by using the control serum, after which VPA was added. The resulting sample solution was subjected to VPA concentration determination by LC-MS. The results
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The detection limit of VPA by SIM mode of LC-MS at a signal-to-noise ratio of 2:1 is 500 ng/ml. Moreover, a tenfold higher signal for the deprotonated molecule was observed after addition of ammonium acetate, when compared with 90% methanol alone as the mobile phase.
Recovery test
Recovery percentage and the relative standard deviation (RSD, n = 4) were examined with the spiked control serum at the range of 13 -262 µg/ml of VPA serum level. As shown in Table 1 , the recovery percentage and RSD were 91.0 -101.5% and 2.2 -4.6%, respectively. The recovery test results demonstrated that the proposed method could be applied to the determination of serum VPA in epileptic patients.
Application to patient serum
The proposed method was applied to the serum of epileptic patients (n = 8, age 7 -25) receiving VPA (sodium valproate, Depakene ® tablet) orally. The mass spectrum of the patient serum is shown in Fig. 2B . The analytical data were compared with those obtained with GC run parallel with the proposed method. As shown in Table 2 , the correlation between the proposed method and GC was r = 0.750. The reason why several results deviated from the regression curve is not clear. The unclarified phenomenon is also described in the paper for the GC analysis of VPA. 7 We attempt to obtain new interpretations about the deviation of the analytical data. Thus, the method gives satisfactory results with serum samples, and was shown to be useful for easy therapeutic drug monitoring with VPA in epileptic patients after VPA oral administration.
Conclusions
The determination of serum VPA pretreated with Extrelut column was examined using LC-APCI-MS technique. The present method employs a simple and rapid solid phase extraction, enabling several samples to be extracted and analyzed without emulsion formation. The addition of acetic acid-ammonium acetate to the injection solution induced a large increase in the intensity of quasimolecule VPA ion signal on SIM mode. Using 20 µl of serum sample, VPA was sensitively determined without chemical derivatization. The proposed method was successfully applied to the monitoring of serum VPA levels in patients. 
